Horizon Pharma

Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets seven medicines through its orphan, primary care and specialty business units. Horizon's global headquarters are in Dublin, Ireland.
Company Growth (employees)
Type
Public
HQ
Ballsbridge, IE
Founded
2008
Size (employees)
1,030 (est)-1%
Horizon Pharma was founded in 2008 and is headquartered in Ballsbridge, IE

Key People at Horizon Pharma

Jeffrey D. Kent

Jeffrey D. Kent

Senior Vice President, Medical Affairs & Outcomes Research
Brian Beeler

Brian Beeler

Chief Compliance Officer and Vice President, Associate General Counsel
Amy Grahn

Amy Grahn

Senior Vice President, Clinical Development and Operations
Robert De Vaere

Robert De Vaere

Executive Vice President and Chief Financial Officer
Ben Bove

Ben Bove

Senior Vice President, Marketing & Commercial Analytics

Horizon Pharma Office Locations

Horizon Pharma has offices in Ballsbridge, Lake Forest, Mannheim, Reinach and in 2 other locations
Ballsbridge, IE (HQ)
Connaught House Burlington Rd
Chicago, US
3200 150 S Wacker Dr
Roswell, US
270 1000 Holcomb Woods Pkwy
Reinach, CH
17 Kägenstrasse
Mannheim, DE
13 Joseph-Meyer-Straße
Lake Forest, US
Landmark of Lake Forest 2 150 S Saunders Rd

Horizon Pharma Data and Metrics

Horizon Pharma Financial Metrics

Horizon Pharma's revenue was reported to be $220.9 m in Q1, 2017
USD

Revenue (Q1, 2017)

220.9 m

Gross profit (Q1, 2017)

81.7 m

Gross profit margin (Q1, 2017), %

37%

Net income (Q1, 2017)

(90.6 m)

EBIT (Q1, 2017)

(105.4 m)

Market capitalization (15-Sep-2017)

2 b

Closing share price (15-Sep-2017)

12.3

Cash (31-Mar-2017)

603.4 m
Horizon Pharma's current market capitalization is $2 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

74 m297 m757 m981.1 m

Revenue growth, %

301%155%30%

Cost of goods sold

14.6 m76.8 m219.5 m393.3 m

Gross profit

59.4 m220.2 m537.5 m587.8 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

66.1 m75.1 m113.1 m172.8 m226.5 m204.7 m257.4 m208.7 m220.9 m

Cost of goods sold

24.8 m13.6 m28.9 m61.8 m61.3 m77.2 m81.1 m85.2 m139.1 m

Gross profit

41.3 m61.5 m84.3 m111 m165.3 m127.5 m176.3 m123.5 m81.7 m

Gross profit Margin, %

62%82%74%64%73%62%68%59%37%
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

80.5 m218.8 m859.6 m509.1 m

Accounts Receivable

16 m78.4 m210.4 m305.7 m

Inventories

4.9 m14.4 m15.9 m174.8 m

Current Assets

110.8 m329.2 m1.1 b1 b
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

128.9 m248.8 m544.2 m667.1 m684.3 m385.9 m424.5 m549.3 m603.4 m

Accounts Receivable

51.8 m80 m127.3 m182.9 m221.1 m290.3 m304.4 m362.9 m396.8 m

Inventories

9.2 m23.8 m13.6 m20.3 m17.7 m180.2 m172.1 m162.2 m137.8 m

Current Assets

197.7 m360.8 m735.9 m898.2 m953.6 m876.6 m938 m1.1 b1.2 b
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(149 m)(263.6 m)39.5 m(166.8 m)

Depreciation and Amortization

9.3 m34 m138.3 m221.8 m

Accounts Receivable

(12 m)(51 m)(120 m)(67.5 m)

Inventories

(3.4 m)7.2 m12.2 m67.6 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(27.8 m)2.1 m(19.6 m)31.8 m3.3 m(45.4 m)15 m(5.9 m)(90.6 m)

Accounts Receivable

51.8 m80 m127.3 m182.9 m221.1 m290.3 m304.4 m362.9 m396.8 m

Accounts Payable

15.9 m22.2 m22 m26.2 m62.1 m69.7 m59 m65.7 m87.7 m
USDY, 2017

Revenue/Employee

212.4 k

Financial Leverage

3.6 x
Show all financial metrics

Horizon Pharma Market Value History

Traffic Overview of Horizon Pharma

Horizon Pharma Online and Social Media Presence

Horizon Pharma News and Updates

How free coupons for patients help drugmakers hike prices by 1,000%

Horizon Pharma charges more than $2,000 for a month’s supply of a prescription pain reliever that is the combination of two cheap drugs available separately over the counter. Another company, Novum, sells a small tube of a prescription skin rash cream, containing two inexpensive decades-old medi…

It looks as though there's only one thing big drug companies are afraid of

As earnings season marches along, it's increasingly clear that there's only one thing that scares big drug companies, and that's losing pricing power to other actors in the healthcare market. Based on what we're seeing, some of that power is already slipping away. And mostly…

The newest pharma villain Novum is charging $9,561 for a tube of skin cream

Mylan CEO Heather Bresch is being grilled by Congress Sept. 21 over the pricing of the EpiPen, which has climbed 400% since her company acquired…

Horizon Pharma Is Buying Raptor to Build Up Its Rare Disease Treatments

As part of an overall expansion plan

Term Sheet — Monday, September 12

term sheet

BRIEF-Horizon pharma Q2 diluted earnings per share $0.09

* Horizon Pharma Plc announces second-quarter 2016 financial results
Show more

Horizon Pharma Company Life and Culture

You may also be interested in